“Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study”, RSD, vol. 11, no. 5, p. e55811528662, Apr. 2022, doi: 10.33448/rsd-v11i5.28662.